Last reviewed · How we verify
Nattokinase
At a glance
| Generic name | Nattokinase |
|---|---|
| Also known as | nattokinase-mono formula (3500FU), Nattokinase compound-multiple formulae, Placebo |
| Sponsor | Chi Mei Medical Hospital |
| Drug class | Vitamin C [EPC] |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of Nattokinase on Cardiovascular Risk, Gut Microbiota, Sleep, and Cognition in Metabolic Syndrome With Sleep Disorders. (NA)
- Hormone Estradiol Replacement Therapy Additional Herbals (PHASE4)
- Effects of Nattokinase on Inflammation and Cardiovascular Risk Markers in Patients With Dyslipidemia (NA)
- Nattokinase Atherothrombotic Prevention Study (NA)
- Improving Cerebral Blood Flow and Cognitive Function in Patients With Asymptomatic Intracranial / Carotid Stenosis With Nattokinase (ICC-PACS) (NA)
- Nattokinase Supplementation and Hemostatic Factors (PHASE4)
- Effects of NSK-SD (Nattokinase) on Blood Pressure (PHASE4)
- Study of the Cardiovascular Vitamin, CardioLife (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nattokinase CI brief — competitive landscape report
- Nattokinase updates RSS · CI watch RSS
- Chi Mei Medical Hospital portfolio CI